Marimar Benitez
A5017286464- Advanced Breast Cancer Therapies
- Physiological and biochemical adaptations
- Neurobiology and Insect Physiology Research
- Cancer-related Molecular Pathways
- Genetics, Aging, and Longevity in Model Organisms
- Reproductive Biology and Fertility
- Viral Infectious Diseases and Gene Expression in Insects
- Cancer-related cognitive impairment studies
- Robotics and Sensor-Based Localization
- Cerebrovascular and Carotid Artery Diseases
- Cultural Industries and Urban Development
- Telomeres, Telomerase, and Senescence
- Spatial Cognition and Navigation
- RNA Interference and Gene Delivery
- Architecture, Art, Education
- Pluripotent Stem Cells Research
- PARP inhibition in cancer therapy
- Complement system in diseases
- Monoclonal and Polyclonal Antibodies Research
- 3D Printing in Biomedical Research
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Robotic Path Planning Algorithms
Kettering University
2024
Memorial Sloan Kettering Cancer Center
2023-2024
Cornell University
2023-2024
University of California, San Francisco
2016-2019
Despite extensive knowledge about the transcriptional regulation of stem cell differentiation, less is known role dynamic cytosolic cues. We report that an increase in intracellular pH (pHi) necessary for efficient differentiation Drosophila adult follicle cells (FSCs) and mouse embryonic (mESCs). show pHi increases with from FSCs to prefollicle (pFCs) cells. Loss Na
Inhibition of CDK4/6 kinases has led to improved outcomes in breast cancer. Nevertheless, only a minority patients experience long-term disease control. Using large, clinically annotated cohort with metastatic hormone receptor-positive (HR+) cancer, we identify TP53 loss (27.6%) and MDM2 amplification (6.4%) be associated lack Human cancer models reveal that p53 does not alter activity or G1 blockade but instead promotes drug-insensitive p130 phosphorylation by CDK2. The persistence...
Abstract Purpose: We conducted research on CDK4/6 inhibitors (CDK4/6i) simultaneously in the preclinical and clinical spaces to gain a deeper understanding of how senescence influences tumor growth humans. Patients Methods: coordinated first-in-kind phase II trial CDK4/6i abemaciclib for patients with progressive dedifferentiated liposarcoma (DDLS) cellular studies interrogating molecular basis geroconversion. Results: Thirty progressing DDLS enrolled were treated 200 mg twice daily. The...
<p>Quantification of the Abemaciclib induced changes in ANGPTL4 expression each patient</p>
<p>Relationship between CDH18 expression, MDM2 downregulation, and ANGPTL4 mRNA expression in patients treated with abemaciclib</p>
<p>Durable quiescence can be established in LS8817tetONFMDM2 cells</p>
<p>Abemaciclib induced changes in CD8+ TILs individual patients</p>
<p>Patient toxicities graded according to the National Cancer Institute's common terminology criteria for adverse events, version 4.0</p>
<p>Patient toxicities graded according to the National Cancer Institute's common terminology criteria for adverse events, version 4.0</p>
<p>Metabolome profiles of LS8817tetONFMDM2 undergoing cell cycle exit and geroconversion</p>
<div>AbstractPurpose:<p>We conducted research on CDK4/6 inhibitors (CDK4/6i) simultaneously in the preclinical and clinical spaces to gain a deeper understanding of how senescence influences tumor growth humans.</p>Patients Methods:<p>We coordinated first-in-kind phase II trial CDK4/6i abemaciclib for patients with progressive dedifferentiated liposarcoma (DDLS) cellular studies interrogating molecular basis geroconversion.</p>Results:<p>Thirty progressing...
<p>Increases in ANGPTL4 are not associated with palbociclib induced senescence ER+ breast cancer cell lines</p>
<p>Effect of shRNA hairpins on geroconversion when introduced into quiescent DDLStetONFDM2 cells</p>
<p>Effect of shRNA hairpins on geroconversion when introduced into quiescent DDLStetONFDM2 cells</p>
<p>ANGPTL4 is the most widely expressed and highly enriched transcript in treated cells compared to untreated cells</p>
<p>Durable quiescence can be established in LS8817tetONFMDM2 cells</p>
<p>Abemaciclib induced changes in FOXP3+ TILs individual patients</p>
<p>Palbociclib does not induce DNA damage in senescent LS8817 cells</p>
<p>ANGPTL4 is necessary to drive senescence in palbociclib treated A549 cells</p>
<p>Quantification of the Abemaciclib induced changes in ANGPTL4 expression each patient</p>